New drug shows promise for Hard-to-Treat cancers
NCT ID NCT02661542
First seen Apr 25, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study tested a new drug called FF-10502-01 in 106 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. The study is now complete, and results help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sarah Cannon Research Institute at HealthOne
Denver, Colorado, 80218, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.